Apogee Therapeutics (APGE) Insider Trading & Ownership $47.25 -3.76 (-7.37%) (As of 11/15/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Apogee Therapeutics (NASDAQ:APGE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage36.10%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$9.13 M Get APGE Insider Trade Alerts Want to know when executives and insiders are buying or selling Apogee Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address APGE Insider Buying and Selling by Quarter Ad WealthPressThe Tesla Trade Is Back In BusinessIf you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Apogee Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/6/2024Carl DambkowskiInsiderSell6,665$59.12$394,034.80 11/6/2024Michael Thomas HendersonCEOSell15,000$59.22$888,300.00 10/2/2024Carl DambkowskiInsiderSell6,665$56.26$374,972.90 10/2/2024Michael Thomas HendersonCEOSell40,000$56.23$2,249,200.00 9/4/2024Carl DambkowskiInsiderSell6,665$47.56$316,987.40 9/4/2024Michael Thomas HendersonCEOSell40,000$47.62$1,904,800.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 8/23/2024Jane HendersonCFOSell6,000$48.26$289,560.00 8/7/2024Carl DambkowskiInsiderSell7,335$40.67$298,314.45 8/7/2024Michael Thomas HendersonCEOSell40,000$40.62$1,624,800.00 7/5/2024Michael Thomas HendersonCEOSell15,000$37.26$558,900.00 7/3/2024Carl DambkowskiInsiderSell5,995$37.60$225,412.00 (Data available from 1/1/2013 forward) APGE Insider Trading Activity - Frequently Asked Questions Who is on Apogee Therapeutics's Insider Roster? The list of insiders at Apogee Therapeutics includes Carl Dambkowski, Jane Henderson, Michael Thomas Henderson, and Nimish P Shah. Learn more on insiders at APGE. What percentage of Apogee Therapeutics stock is owned by insiders? 36.10% of Apogee Therapeutics stock is owned by insiders. Learn more on APGE's insider holdings. Which Apogee Therapeutics insiders have been buying company stock? The following insider purchased APGE shares in the last 24 months: Nimish P Shah ($29,750,000.00). How much insider buying is happening at Apogee Therapeutics? Insiders have purchased a total of 1,750,000 APGE shares in the last 24 months for a total of $29,750,000.00 bought. Which Apogee Therapeutics insiders have been selling company stock? The following insiders have sold APGE shares in the last 24 months: Carl Dambkowski ($1,609,721.55), Jane Henderson ($289,560.00), and Michael Thomas Henderson ($7,226,000.00). How much insider selling is happening at Apogee Therapeutics? Insiders have sold a total of 189,325 Apogee Therapeutics shares in the last 24 months for a total of $9,125,281.55 sold. Apogee Therapeutics Key ExecutivesDr. Michael Thomas Henderson M.D. (Age 34)CEO & Director Compensation: $1.17M5 recent tradesMs. Jane Pritchett V. Henderson (Age 58)Chief Financial Officer Compensation: $843.64kDr. Carl Linden Dambkowski M.D. (Age 38)Chief Medical Officer Compensation: $870.83kMs. Noel KurdiVice President of Investor RelationsMr. Matthew Batters J.D. (Age 48)Chief Legal Officer & Corporate Secretary Ms. Emily CoxVP & Head of PeopleDr. Rebecca Dabora Ph.D. (Age 64)Chief Development Officer Ms. Wendy Aspden-CurranSenior Vice President of Clinical OperationsDr. Drew Badger Ph.D.Senior VP and Head of Regulatory Affairs & ToxicologyMs. Monica Forbes (Age 48)Senior Vice President of Finance More Insider Trading Tools from MarketBeat Related Companies RVMD Insider Trading ITCI Insider Trading ROIV Insider Trading VKTX Insider Trading ELAN Insider Trading CYTK Insider Trading BPMC Insider Trading LNTH Insider Trading NUVL Insider Trading ACLX Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics Partners This page (NASDAQ:APGE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APGE Stock Alerts